Liver Cancer Diagnostics Market Size to Worth US$ 20.4 Bn by 2030

According to Vision Research Reports, the liver cancer diagnostics market size is expected to be worth around US$ 20.4 billion by 2030 from valued at US$ 10.7 billion in 2020 and is anticipated to grow at a CAGR of 8.5% from 2021 to 2030.

Growth Factors

Rise in the number of programs to raise awareness about early diagnosis of liver cancer is also expected to be a key factor responsible for increasing the demand for its diagnostic products worldwide. The major risk factors for this disease include chronic viral hepatitis, Cirrhosis, heavy alcohol consumption, tobacco consumption, and obesity. Early screening and diagnosis of liver cancer is the core stone for the control of related mortality, thus, creates a high demand for innovative diagnostics tests. Liver cancer is one of the leading causes of cancer-related deaths around the world. According to the American Cancer Society, in the past few decades, the incidence rates of liver cancer have more than tripled and the death rates have more than doubled during this time.

Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38898

By Test Type Analysis

The laboratory tests segment dominated the market for liver cancer diagnostics and accounted for the largest revenue share of 39.5%. The segment is projected to grow at the fastest rate during the forecast period. This large share and growth can be attributed to the high preference for laboratory tests due to their accuracy and cost-efficiency.

The imaging tests segment accounted for the second-largest revenue share and is anticipated to show significant growth throughout the study period. Imaging tests can be supportive tests for laboratory and genetic tests that help confirm the presence of a tumor. Imaging tests include Computed Tomography (CT) scan, Magnetic Resonance Imaging (MRI) scan, X-ray, ultrasound, and other radiographic tests.

Report Coverage

By End-use Analysis

The hospitals and diagnostic laboratories segment dominated the market for liver cancer diagnostics in 2020 and accounted for the largest revenue share of 83.4%. Hospitals are primary care settings for the diagnosis and treatment of medical conditions including hepatocellular carcinoma.

The pharmaceutical and CRO laboratories segment is anticipated to witness the fastest CAGR during the forecast period. This high growth can be attributed to the high demand for liver diagnostics solutions by leading pharmaceutical companies for research purposes.

By Regional Analysis

North America dominated the liver cancer diagnostics market and accounted for the largest revenue share of 40.1% in 2020 and is projected to remain dominant throughout the forecast period. 

In Asia Pacific, the market for liver cancer diagnostics is expected to exhibit the highest growth throughout the study period. This high growth can be attributed to the high prevalence of Hepatitis in emerging countries including India and China.

Key Players

• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Qiagen N.V.
• Thermo Fisher Scientific, Inc.
• Siemens Healthineers
• Becton Dickinson & Company
• Illumina, Inc.
• Koninklijke Philips N.V.
• Epigenomics AG
• Fujifilm Medical Systems U.S.A., Inc.

Market Segmentation

• By Test Type 
  • Laboratory Tests
    • Biomarkers
      • Oncofetal and Glycoprotein Antigens
      • Enzymes and Isoenzymes
      • Growth Factors and Receptors
      • Molecular Markers
      • Pathological Biomarkers
    • Blood Tests
  • Imaging Tests
  • Endoscopy
  • Biopsy
  • Others 
• By End-use
  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & CRO Laboratories
• Regional
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Click Here to View Full Report Table of Contents

Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38898

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333